Trevena Inc Financials and Recent Developments

Trevena Inc has a market capitalization of around $1.3 billion. The company is a biopharmaceutical firm focused on developing innovative treatments for pain and other serious conditions.

Trevena's lead product candidate is Oliceridine, a G protein biased opioid receptor agonist.

The company has received regulatory approval for Oliceridine in the United States.

Trevena, Inc. has a market capitalization of $1.3 billion. The company's revenue for 2020 was $12 million.

Trevena's net loss for 2020 was $104 million. This significant loss highlights the challenges the company has faced in recent years.

Trevena's cash and cash equivalents stood at $63 million at the end of 2020.

Trevena, Inc. recently closed a $4 million concurrent private placement and warrant exercise. This significant funding boost will help the biopharmaceutical company continue its mission of developing and commercializing novel medications.

The private placement and warrant exercise were announced on December 27, 2023, and December 28, 2023, respectively. This timing is notable, as it coincides with the company's fiscal period, which ends in December.

The funding will undoubtedly support Trevena's efforts to develop and commercialize its pharmaceutical products. The company's focus on discovering and developing novel medications has been a key aspect of its business description for several years.

Here's a brief overview of Trevena's business description and recent funding:

Trevena recently received a $15 million non-dilutive tranche from ex-US royalty-based financing. This funding was triggered by the first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China.

The company is also preparing for several upcoming events, including the American Society of Anesthesiologists Meeting in 4Q 2023, where three OLINVYK abstracts will be presented.

Trevena will participate in the HC Wainwright conference on September 11-13, and the company will hold a conference call on September 6 to discuss TRV045 Proof-of-Concept Data.

The $15 million tranche is a significant financial boost for the company, allowing them to continue their research and development efforts.

For another approach, see: Cassa Centrale Banca - Credito Cooperativo Italiano

A reverse stock split is a move Trevena has made to regain compliance with Nasdaq's $1.00 minimum bid price requirement.

Trevena's reverse stock split is effective as of August 13, 2024, with a 1-for-25 ratio. This means that every 25 shares of the company's common stock will be consolidated into one share.

The company's common stock will continue to trade under the symbol 'TRVN' on the Nasdaq Capital Market, with a new CUSIP number 89532E 307. The split will affect all outstanding shares, equity incentive plans, and adjust stock options and warrants.

No fractional shares will be issued; instead, affected stockholders will receive cash payments. This decision follows stockholder approval at the June 13, 2024 Annual General Meeting.

Trevena has also secured non-dilutive financing, receiving $2 million from R-Bridge Healthcare Fund, with potential for an additional $8 million based on OLINVYK's US commercialization milestones.

Curious to learn more? Check out: Johnson and Johnson Shares Outstanding

Trevena, Inc. has reported favorable safety and tolerability data from proof-of-concept studies for its TRV045 product.

The company's TRV045 was well tolerated in the studies, with no drug-related adverse events or serious adverse events reported.

Trevena's TRV045 also showed no evidence of receptor desensitization in a preclinical model of neuropathic pain.

This is promising news for the company's neurological disease-focused product pipeline.

Here's a breakdown of Trevena's fiscal periods:

This data suggests that Trevena's business model is focused on developing pharmaceutical products, and the company has experienced fluctuations in revenue over the past few years.

Trevena, Inc. has had its fair share of ups and downs in the stock market.

The current share price is a mere $0.012, a far cry from its 52-week high of $2.35. This significant drop is a stark reminder of the volatility of the market.

In the past month, the stock has experienced a 20% increase, which is a positive sign. However, over the past three months, it has plummeted by 98.68%.

Looking at the bigger picture, the stock has seen a massive decline of 99.40% over the past year. This is a concerning trend for investors.

Here's a summary of the stock's performance over different time periods:

As you can see, the stock's performance has been inconsistent, to say the least.

Trevena, Inc. has a robust risk management program in place, which includes regular audits and assessments to identify and mitigate potential risks.

The company has identified several key risks, including regulatory risks related to the approval and commercialization of its products, as well as operational risks related to manufacturing and supply chain disruptions.

Trevena's compliance program is designed to ensure that the company meets all applicable laws and regulations, including those related to pharmaceutical development and marketing.

Recommended read: Affordable Care Act Health Insurance Rate Review Program

A company's financial health is a crucial aspect of risk analysis. Revenue has declined by a staggering 83% over the past year.

This significant decline in revenue is a major red flag, with the company now making less than USD$1m in revenue, a far cry from the six-figure mark of $546K.

Negative shareholders equity is another alarming sign, indicating that the company's liabilities exceed its assets.

In this case, the company has multiple risks, including a significant drop in revenue and a substantial decline in shareholders equity.

Trevena, a biopharmaceutical company, received a delisting notification from the Nasdaq Hearings Panel on October 4, 2024.

The company failed to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1).

Trading of Trevena's common stock on Nasdaq will be suspended effective October 8, 2024.

The company expects its common stock to begin trading on the Pink Open Market operated by OTC Markets Group.

For more insights, see: Russian Steam Navigation and Trading Company

However, there is no assurance that a broker will continue to make a market in the company's stock or that trading will continue on an over-the-counter market or elsewhere.

Trevena received notice that the Nasdaq Hearings Panel had determined to delist the Company's common stock from The Nasdaq Stock Market LLC due to the Company's failure to comply with the minimum stockholder's equity requirement.

The Panel had provided the Company until October 2, 2024, to regain compliance, but the Company failed to do so.

Trevena will receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones.

Worth a look: Muscat Securities Market

Trevena, a biopharmaceutical company, regained compliance with Nasdaq listing requirements. They achieved this milestone in May 2023.

Regaining Nasdaq compliance is a significant achievement for Trevena, as it allows them to continue trading on the stock exchange. This is a crucial step for the company's growth and development.

Trevena is focused on developing and commercializing novel medicines for patients with central nervous system disorders. Their pipeline includes OLINVYK, a medication for severe pain.

The company is eligible for non-dilutive funding of up to $10 million, based on partnering and commercialization milestones. This funding will help support the development and commercialization of OLINVYK.

Trevena has made significant progress in the development and commercialization of OLINVYK. They have received a milestone payment of $3 million from a partner in China for the Chinese approval of OLINVYK.

Trevena, Inc. is a biopharmaceutical company with a dedicated team of experts.

The company's headquarters is located in Malvern, Pennsylvania.

Trevena, Inc. has a strong commitment to its shareholders, providing them with regular updates and information.

When evaluating the performance of a company, one key metric to consider is shareholder returns. Over the past seven days, TRVN's shareholder returns were flat at 0%.

The company's one-year performance is a different story, with a decline of 99.4%. In comparison, the US Biotechs industry returned 3.1% over the same period.

The US Market, on the other hand, saw a significant increase of 16.3% in the same timeframe. TRVN underperformed both the US Biotechs industry and the US Market over the past year.

Here's a summary of the shareholder returns for TRVN and its industry peers:

TRVN's underperformance is evident when comparing its returns to the industry and market averages.

Insider trading is a key aspect of shareholder information. Insider transactions can reveal the sentiment of key stakeholders about the company.

Insider transactions are publicly disclosed and can be viewed in real-time. This transparency allows investors to make informed decisions.

The "$TRVN Insider Trading" feed provides live updates on insider transactions. This feed is a valuable resource for investors who want to stay up-to-date on the company's inner workings.

Insider trading can be a sign of confidence or lack thereof in the company. For example, a high-level executive selling a large amount of stock may indicate a lack of confidence in the company's future prospects.

Insider trading is a closely monitored activity, and any suspicious activity can lead to penalties.

Sutton Katrine claimed ownership of 942 shares.

TREVENA INC is the issuer mentioned in the report.

Sutton Katrine's ownership stake is a significant one, with 942 shares being a notable amount.

The SEC Form 3 filing is the source of this information, providing transparency into the ownership structure of TREVENA INC.

This filing is a crucial document for investors and analysts, offering a snapshot of the company's shareholder landscape.

Curious to learn more? Check out: Sofi Shares Outstanding

Trevena, Inc. operates in a competitive market, but unfortunately, there's insufficient data to determine the company's volatility change over the past year.

The lack of volatility data makes it difficult to assess the company's performance in relation to its competitors.

One thing is certain, though - Trevena, Inc. has competitors, but we don't have enough information to compare their performance.

Trevena, Inc. faces competition, but we can't analyze the dynamics of this competition due to limited data.

Here's an interesting read: T K Group of Industries

Trevena, Inc. has a President and CEO named Carrie Bourdow.

Carrie Bourdow is the President and CEO of Trevena, Inc. She's the one making key decisions for the company.

The company's Board of Directors has a new member, Mark Corrigan, M.D. He was appointed to the Board on July 18, 2023, and brings over 30 years of experience in the life sciences industry.

Trevena, Inc. is a company that focuses on discovering and developing pharmaceutical products. Their business description is straightforward.

In 2020, the company reported 3.07 million in revenue from this focus. This is a significant milestone for the company.

The company's revenue from discovering and developing pharmaceutical products has fluctuated over the years. In 2021, the revenue was 567 thousand, and in 2022, it was -418 thousand.

Here's a breakdown of the company's revenue from this focus over the years:

The Executive Committee of Trevena, Inc. is responsible for making key decisions for the company. Carrie Bourdow serves as the CEO, a position she has held since September 30, 2018. She is 62 years old. Joel S. Solomon has been the Compliance Officer since January 31, 2015.

The company has multiple Chief Technology/Science/R&D Officers, which might seem unusual. However, having multiple individuals in this role could indicate a large and complex R&D department.

Mark Demitrack, a 67-year-old, has been the Chief Technology/Science/R&D Officer since May 20, 2018.

Intriguing read: Oxford Science Enterprises

The Board of Directors at Trevena, Inc. is made up of experienced professionals who bring a wealth of knowledge and expertise to the table.

Barbara Yanni has been a Director/Board Member since 2014. She's been a part of the team for over eight years.

Carrie Bourdow serves as the Chairman, a role she took on in 2023. She's been instrumental in guiding the company's direction.

Mark Corrigan, M.D. joined the Board of Directors in July 2023, bringing over 30 years of experience in the life sciences industry.

Here's a snapshot of the current Board of Directors composition:

Trevena's leadership team is responsible for guiding the company's growth and development. They have a strong track record of success in the biopharmaceutical industry.

The company received a $15 million non-dilutive tranche from ex-US royalty-based financing, triggered by the first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China.

Trevena's focus on neurological disease has led to promising results in nonclinical models of neuropathic pain. Their TRV045 candidate shows potential for sustained, long-term analgesic effect.

The company's research has demonstrated statistically significant analgesic effect in a capsaicin-induced model of neuropathic pain. This is a significant breakthrough in the treatment of neuropathic pain.

Trevena's partnership with Jiangsu Nhwa has been instrumental in the commercial success of OLINVYK. The company's ability to partner with other organizations has been a key factor in its growth.

TRV045 has shown no evidence of receptor desensitization, a common issue in pain management treatments. This is a significant advantage for Trevena's candidate.

Trevena, Inc. regularly files various documents with the Securities and Exchange Commission (SEC).

These filings provide valuable information about the company's financial and operational activities.

Trevena, Inc. has filed NT 10-K forms with the SEC, which are annual reports that provide detailed information about the company's financial condition and results of operations.

SEC Form SC 13G/A and SC 13G filings are also associated with Trevena, Inc., indicating the company's involvement in certain transactions or changes in ownership.

The company's CUSIP number, 0001429560, is consistently referenced in these filings, serving as a unique identifier for Trevena, Inc.

Check this out: Oil Price Information Service

Trvn Analyst Ratings are displayed in real time, showing their high impact on the underlying stock.

Analyst ratings are a crucial factor that can influence the price of Trevena, Inc. stock.

The live feed shows all institutional transactions in real time, giving you a glimpse into the market's current activity.

This live feed is a valuable tool for investors who want to stay up-to-date on market trends and make informed decisions.

Curious to learn more? Check out: Paramount Communications, Inc. V. Time Inc.

Trevena, Inc. has made significant strides in its partnerships and milestones. The company received a $3 million milestone payment from its partner in China, Jiangsu Nhwa Pharmaceutical, for the Chinese approval of OLINVYK (oliceridine) injection.

This achievement is a testament to the company's dedication to expanding its reach and making its innovative medicines available to patients worldwide. Trevena is also eligible to receive $15 million in non-dilutive financing from R-Bridge upon the first commercial sale of OLINVYK.

Trevena has also secured a significant agreement with Premier, Inc., a leading healthcare improvement company in the United States.

Trevena Inc. was awarded an OLINVYK agreement with Premier, Inc. in December 2023. This agreement is a significant partnership for the company.

Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines. The company has a strong focus on patient care.

Premier, Inc. is a leading healthcare improvement company. They work with hospitals and health systems to improve patient outcomes.

The OLINVYK agreement is a key partnership for Trevena. It will help the company expand its reach in the market.

You might enjoy: Premier Education Group

Trevena received a significant milestone payment from its partner in China, Jiangsu Nhwa Pharmaceutical, which was $3 million for the Chinese approval of OLINVYK (oliceridine) injection.

This payment is a testament to the growing importance of international partnerships in the pharmaceutical industry.

The company is also eligible to receive $15 million non-dilutive financing from R-Bridge upon the first commercial sale of OLINVYK in China.

You might like: West Pharmaceutical Services